Compare AVX & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AVX | LTRN |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | Canada | United States |
| Employees | 7 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.2M | 46.8M |
| IPO Year | N/A | 2020 |
| Metric | AVX | LTRN |
|---|---|---|
| Price | $5.37 | $3.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 108.1K | ★ 183.8K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.35 | $1.11 |
| 52 Week High | $6.40 | $5.74 |
| Indicator | AVX | LTRN |
|---|---|---|
| Relative Strength Index (RSI) | 67.32 | 50.22 |
| Support Level | $4.80 | $3.09 |
| Resistance Level | $6.32 | $3.79 |
| Average True Range (ATR) | 0.57 | 0.35 |
| MACD | -0.16 | -0.10 |
| Stochastic Oscillator | 38.24 | 46.51 |
AVAX One Technology Ltd is a digital infrastructure company focused on digital asset and computing infrastructure. The Company builds modular data centers in regions with access to energy resources, using behind-the-meter generation and microgrid design to provide compute capacity for AI and high-performance computing (HPC) workloads. In addition, the company mines Bitcoin in Alberta and Ohio, operating at a hashrate of approximately 300 PH/s. The Company also maintains an Avalanche digital asset treasury, accumulating AVAX and generating onchain yield through native staking and ecosystem participation.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.